Skip to main content

Quest Diagnostics Incorporated (DGX) Stock Analysis

Range Bound setup

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Diagnostics & Research

Sell if holding. At $193.24, A.R:R 0.7:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Negative momentum; Thin upside margin: 4.1%.

Quest Diagnostics provides diagnostic testing services to approximately one-third of the US adult population annually, serving physicians, hospitals, patients, health plans, and employers. Generated $11.0B in revenue in 2025 from clinical lab testing and related services.

$193.24+4.1% A.UpsideScore 5.2/10#14 of 25 Diagnostics & Research
Stop $181.88Target $200.81(analyst − 10%)A.R:R 0.7:1
Analyst target$223.13+15.5%16 analysts
$200.81our TP
$193.24price
$223.13mean
$184
$245

Sell if holding. At $193.24, A.R:R 0.7:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Negative momentum; Thin upside margin: 4.1%. Chart setup: RSI 52 mid-range, Bollinger mid-band. Score 5.2/10, moderate confidence.

Passes 5/7 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 82d clear, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.

Thesis

Rewards
Strong earnings beat streak (4/4)
Risks
Thin upside margin: 4.1%
Negative momentum

Key Metrics

P/E (TTM)20.9
P/E (Fwd)16.2
Mkt Cap$21.0B
EV/EBITDA12.3
Profit Mgn9.1%
ROE14.5%
Rev Growth9.2%
Beta0.65
Dividend1.82%
Rating analysts24

Quality Signals

Piotroski F7/9

Options Flow

P/C1.37bearish
IV36%normal
Max Pain$100-48.3% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMSupplierthird-party billing operations
    10-K Item 1A: 'The majority of billing and related operations for our Company are being provided by a third party under the Company’s oversight.'

Material Events(8-K, last 90d)

  • 2026-03-12Item 5.02LOW
    Board elected Timothy Wentworth (former CEO of Walgreens Boots Alliance) as director on March 9, 2026. Added to Compensation and Quality/Compliance Committees.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Volume
0.0
Obv
1.0
Ma Position
4.0
Rsi
5.5
Volume distribution (falling OBV)Above 200-day MA
GatesMomentum 2.1<4.5A.R:R 0.7 < 1.5@spotInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 82d clearSEMI CYCLE PEAK CLEARRange BoundSuitability: Moderate
RSI
52 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $187.50Resistance $209.79

Price Targets

$182
$201
A.Upside+3.9%
A.R:R0.7:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Momentum score 2.1/10 — below 4.5 minimum
! Reward/Risk 0.7:1 at current price — below 1.5:1 minimum

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-07-21 (82d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is DGX stock a buy right now?

Sell if holding. At $193.24, A.R:R 0.7:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Negative momentum; Thin upside margin: 4.1%. Chart setup: RSI 52 mid-range, Bollinger mid-band. Prior stop was $181.88. Score 5.2/10, moderate confidence.

What is the DGX stock price target?

Take-profit target: $200.81 (+4.1% upside). Prior stop was $181.88. Stop-loss: $181.88.

What are the risks of investing in DGX?

Thin upside margin: 4.1%; Negative momentum.

Is DGX overvalued or undervalued?

Quest Diagnostics Incorporated trades at a P/E of 20.9 (forward 16.2). TrendMatrix value score: 6.2/10. Verdict: Sell.

What do analysts say about DGX?

24 analysts cover DGX with a consensus score of 3.8/5. Average price target: $223.

What does Quest Diagnostics Incorporated do?Quest Diagnostics provides diagnostic testing services to approximately one-third of the US adult population annually,...

Quest Diagnostics provides diagnostic testing services to approximately one-third of the US adult population annually, serving physicians, hospitals, patients, health plans, and employers. Generated $11.0B in revenue in 2025 from clinical lab testing and related services.

Related stocks: SHC (Sotera Health Company) · QGEN (Qiagen N.V.) · GH (Guardant Health, Inc.) · IQV (IQVIA Holdings, Inc.) · ILMN (Illumina, Inc.)